Curcumin-induced apoptosis in PC3 prostate carcinoma cells is caspase-independent and involves cellular ceramide accumulation and damage to mitochondria

Nutrition and Cancer

Volumn 62, Issue 3, 2010, Pages 379-389

  Hilchie, Ashley L ^a   Furlong, Suzanne J ^a   Sutton, Kimberly ^a   Richardson, Angela ^a   Robichaud, Matthew R J ^a   Giacomantonio, Carman A ^a   Ridgway, Neale D ^a   Hoskin, David W ^a  

^a DALHOUSIE UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; APOPTOSIS INDUCING FACTOR; ASCORBIC ACID; CASPASE 3; CASPASE 8; CASPASE 9; CERAMIDE; CURCUMIN; CYTOCHROME C; EBSELEN; GLUTATHIONE; MITOGEN ACTIVATED PROTEIN KINASE P38; REACTIVE OXYGEN METABOLITE; STRESS ACTIVATED PROTEIN KINASE;

APOPTOSIS; ARTICLE; CANCER CELL; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY; DNA FRAGMENTATION; DRUG EFFECT; ENZYME ACTIVATION; HUMAN; HUMAN CELL; MITOCHONDRION; PROSTATE CARCINOMA;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CASPASES; CELL LINE, TUMOR; CERAMIDES; CURCUMIN; GLUTATHIONE; HUMANS; JNK MITOGEN-ACTIVATED PROTEIN KINASES; MALE; MITOCHONDRIA; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PROSTATIC NEOPLASMS; REACTIVE OXYGEN SPECIES;

EID: 77951141914     PISSN: 01635581     EISSN: None     Source Type: Journal    
DOI: 10.1080/01635580903441238     Document Type: Article

References (50)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, et al.: Cancer statistics, 2009. CA Cancer J Clin 59, 225-249, 2009.
2. Garnick MB: Hormonal therapy in the management of prostate cancer: from Huggins to the present. Urology 49, 5-15, 1997.
3. Crawford ED, Eisenberger MA, McLeod DG, Spaulding JT, Benson R, et al.: A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. N Engl J Med 321, 419-424, 1989.
4. Tannock IF, deWit R, Berry WR,Horti J, PluzanskaA, et al.:Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351, 1502-1512, 2004.
5. Hebert JR, Hurley TG, Olendzki BC, Teas J, Ma Y, et al.: Nutritional and socioeconomic factors in relation to prostate cancer mortality: a crossnational study. J Natl Cancer Inst 90, 1637-1647, 1998.
6. Denis L,MortonMS, andGriffithsK:Diet and its preventive role in prostatic disease. Eur Urol 35, 377-387, 1999.
7. Goel A, Kunnumakkara AB, and Aggarwal BB: Curcumin as "curecumin": from kitchen to clinic. Biochem Pharmacol 75, 787-809, 2008.
8. Dorai T,GehaniN, and Katz A: Therapeutic potential of curcumin in human prostate cancer-I. Curcumin induces apoptosis in both androgen-dependent and androgen-independent prostate cancer cells. Prostate Cancer Prostatic Dis 3, 84-93, 2000.
9. Shankar S and Srivastava RK: Involvement of Bcl-2 family members, phosphatidylinositol 3'-kinase/AKT and mitochondrial p53 in curcumin (diferuloylmethane)-induced apoptosis in prostate cancer. Int J Oncol 30, 905-918, 2007.
10. Choudhuri T, Pal S, Agwarwal ML, Das T, and Sa G: Curcumin induces apoptosis in human breast cancer cells through p53-dependent Bax induction. FEBS Lett 512, 334-340, 2002.
11. Bush JA, Cheung KJ, and Li G: Curcumin induces apoptosis in human melanoma cells through a Fas receptor/caspase-8 pathway independent of p53. Exp Cell Res 271, 305-314, 2001.
12. Mosmann T: Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 65, 55-63, 1983.13.
13. Matzinger P: The JAMtest: a simple assay for DNA fragmentation and cell death. J Immunol Methods 145, 185-192, 1991.
14. FrankfurtOS and KrishanA: Identification of apoptotic cells by formamideinduced DNA denaturation in condensed chromatin. J Histochem Cytochem 49, 369-378, 2001.
15. Punchard NA, Watson DJ, and Thompson RP: Analysis of glutathione in endothelial cells grown in 96 well microtitre plates. Biochem Soc Trans 22, 198S, 1994.
16. Preiss J, Loomis CR, Bishop WR, Stein R, Niedel JE, et al.: Quantitative measurement of sn-1,2-diacylglycerols present in platelets, hepatocytes, and ras- and sis-transformed normal rat kidney cells. J Biol Chem 261, 8597-8600, 1986.
17. Woo JH, Kim YH, Choi YJ, Kim DG, Lee KS, et al.: Molecular mechanisms of curcumin-induced cytotoxicity: induction of apoptosis through generation of reactive oxygen species, down-regulation of Bcl-XL and IAP, the release of cytochrome c and inhibition of Akt. Carcinogenesis 24, 1199-1208, 2003.
18. Moussavi M, Assi K, Gomez-Munoz A, and Salh B: Curcumin mediates ceramide generation via the de novo pathway in colon cancer cells. Carcinogenesis 27, 1636-1644, 2006.
19. Meister A: Glutathione-ascorbic acid antioxidant system in animals. J Biol Chem 269, 9397-9400, 1994.
20. Zucker B, Hanusch J, and Bauer G: Glutathione depletion in fibroblasts is the basis for apoptosis-induction by endogenous reactive oxygen species. Cell Death Differ 4, 388-395, 1997.
21. Gillissen A and Nowak D: Characterization of N-acetylcysteine and ambroxol in anti-oxidant therapy. Respir Med 92, 609-623, 1998.
22. Rose RC: Ascorbic acid metabolism in protections against free radicals: a radiation model. Biochem Biophys Res Commun 169, 430-436, 1990.
23. Sies H: Ebselen, a selenoorganic compound as glutathione peroxidase mimic. Free Rad Biol Med 14, 313-323, 1993.
24. Singh S and Khar A: Biological effects of curcumin and its role in cancer chemoprevention and therapy. Anticancer Agents Med Chem 6, 259-270, 2006.
25. Chignell CF, Bilski P, Reszka KJ, Motten AG, Silk RH, et al.: Spectral and photochemical properties of curcumin. Photochem Photobiol 59, 295-302, 1994.
26. Pettus BJ, Chalfant CE, and Hannun YA: Ceramide in apoptosis: an overview and current perspectives. Biochim Biophys Acta 1585, 114-125, 2002.
27. Chik CL, Li B, Karpinski E, and Ho AK: Ceramide inhibits L-type calcium channel currents in GH3 cells. Mol Cell Endocrinol 218, 175-183, 2004.
28. Perry RJ and Ridgway ND: The role of de novo ceramide synthesis in the mechanism of action of the tricyclic xanthate D609. J Lipid Res 45, 164-173, 2004.
29. Meng A, Luberto C,Meier P, Bai A, Yang S, et al.: Sphingomyelin synthase as a potential target for D609-induced apoptosis in U937 human monocytic leukemia cells. Exp Cell Res 292, 385-392, 2004.
30. Fan M and Chambers TC: Role of mitogen-activated protein kinases in the response of tumor cells to chemotherapy. Drug Resist Updat 4, 253-267, 2001.
31. Chendil D, Ranga RS, Meigooni D, Sathishkumar S, and Ahmed MM: Curcumin confers radiosensitizing effect in prostate cancer cell line PC-3. Oncogene 23, 1599-1607, 2004.
32. Deeb D, Jiang H, Gao X, Divine G, Dulchavsky SA, et al.: Chemosensitization of hormone-refractory prostate cancer cells by curcumin to TRAIL-induced apoptosis. J Exp Ther Oncol 5, 81-91, 2005.
33. 6] sensitizes human prostate cancer cells to tumor necrosis factorrelated apoptosis-inducing ligand/Apo2L-induced apoptosis by suppressing nuclear factor-?B via inhibition of the prosurvival Akt signaling pathway. J Pharmacol Exp Ther 321, 616-625, 2007.
34. Usta M, Wortelboer HM, Vervoort J, Boersma MG, Rietjens IM, et al.: Human glutathione S-transferase-mediated glutathione conjugation of curcumin and efflux of these conjugates in Caco-2 cells. Chem Res Toxicol 20, 1895-1902, 2007.
35. Jaffŕezou J-P, Maestre N, De Mas-Mansat V, Bezombes C, Levade T, et al.: 1998. Positive feedback control of neutral sphingomyelinase activity by ceramide. FASEB J 12, 999-1006, 1998.
36. Mizushima N, Koike R, Kohsaka H, Kuchi Y, Handa S, et al.: Ceramide induces apoptosis via CPP32 activation. FEBS Lett 395, 267-271, 1996.
37. Siskind LJ: Mitochondrial ceramide and the induction of apoptosis. J Bioenerg Biomembr 37, 143-153, 2005.
38. Collett GP and Campbell FC: Curcumin induces c-jun N-terminal kinasedependent apoptosis in HCT116 human colon cancer cells. Carcinogenesis 25, 2183-2189, 2004.
39. Weir NM, Selvendiran K, Kutala VK, Tong L, Vishwanath S, et al.: Curcumin inhibits G2/M arrest and apoptosis in cisplatin-resistant human ovarian cancer cells by modulating Akt and p38 MAPK. Cancer Biol Ther 6, 178-184, 2007.
40. Ashkenazi A and Dixit VM: Death receptors: signaling and modulation. Science 281, 1305-1308, 1998.
41. von Haefen C, Wieder T, Essmann F, Schulze-Osthoff K, Dörken B, et al.: Paclitaxel-induced apoptosis in BJAB cells proceeds via a death receptorindependent, caspases-3/-8-drivenmitochondrial amplification loop. Oncogene 22, 2236-2247, 2003.
42. Budihardjo I, Oliver H, Lutter M, Luo X, and Wang X: Biochemical pathways of caspase activation during apoptosis. Annu Rev Cell Dev Biol 15, 269-290, 1999.
43. Bayir H, Fadeel B, Palladino MJ, Witasp E, Kurnikov IV, et al.: Apoptotic interactions of cytochrome c: redox flirting with anionic phospholipids within and outside of mitochondria. Biochim Biophys Acta 1757, 648-659, 2006.
44. Lorenzo HK, Susin SA, Penninger J, and Kroemer G: Apoptosis inducing factor (AIF): a phylogenetically old, caspase-independent effector of cell death. Cell Death Differ 6, 516-524, 1999.
45. Daugas E, Susin SA, Zamzami N, Ferri KF, Irinopoulou T, et al.: Mitochondrio-nuclear translocation of AIF in apoptosis and necrosis. FASEB J 14, 729-739, 2000.
46. Hsu C-H and Cheng A-L: Clinical studies with curcumin. Adv Exp Med Biol 595, 471-480, 2007.
47. Shoba G, JoyD, Joseph T,Majeed M, Rajendrah R, et al.: Influence of piperine on the pharmacokinetics of curcumin in animals and human volunteers. Planta Med 64, 353-356, 1998.
48. Tamvakopoulos C, Dimas K, Sofianos ZD, Hatziantoniou S, Han Z, et al.: Metabolism and anticancer activity of the curcumin analogue, dimethoxycurcumin. Clin Cancer Res 13, 1269-1277, 2007.
49. Li L, Ahmed B, Mehta K, and Kurzrock R: Liposomal curcumin with and without oxaliplatin: effects on cell growth, apoptosis and angiogenesis in colorectal cancer. Mol Cancer Ther 6, 1276-1282, 2007.
50. Bisht S, Feldmann G, Soni S, Ravi R, Karikar C, et al.: Polymeric nanoparticle-encapsulated curcumin ("nanocurcumin"): a novel strategy for human cancer therapy. J Nanobiotechnology 5, 3, 2007